■ INTRODUCTION
Advances in the field of molecular imaging represent an ongoing effort to improve the physician's ability to detect, monitor, and treat a variety of diseases, including cancer. 1 Linder et al. describes these advances in terms of the development of three classes of molecular imaging probes: nonspecific agents, which fluoresce permanently, a specific or targeted probe that contains a fluorophore, and an activatable smart probe with a fluorophore that will only fluoresce upon enzymatic cleavage or activation via another biological mechanism.
2 In this paper, we report the synthesis of an activatable smart probe designed to detect enzyme activity in lipid metabolism with known cancerous associations.
Lipids play an important role in biological systems as they are known to participate in the regulation of cell signaling. 3 Because many cancers exhibit variations in their metabolic and signaling profiles, enzymes in lipid metabolism have become exciting targets for molecular imaging probes. Phosphocholine (PC) is a lipid metabolite that has been observed in increased levels in prostate, 4−8 brain, 4,6,9−12 and breast 4,9,13−17 cancer cells and solid tumors. Elevated levels of PC have also been associated with the degree of malignancy, 18−20 and decreased levels of PC are observed in response to chemotherapeutic treatment. 21 PC has become an important and distinctive cancer biomarker. To detect PC by an activatable smart probe it is necessary to understand the surrounding biological processes. PC can be produced by multiple metabolic pathways, including the anabolic phosphorylation of choline by choline kinase or as the product of the catabolism of phosphatidylcholine by phospholipase C (PLC), along with diacylglycerol. 22−28 These metabolic processes are considered a potential factor in the irregular choline metabolism observed in a variety of cancers. 29−31 Elevated activity of phosphatidylcholine-specific PLC (PC-PLC) has been observed in a variety of cancer types, including the triple negative breast cancer line, MDA-MB-231. 32 On the basis of these observations, our research efforts have centered on the development of molecular imaging probes that will selectively fluoresce in the presence of PC-PLC.
Previously, we reported the synthesis and selectivity of an activatable smart probe that selectively fluoresces in the presence of PC-PLC. 22−24 This specific activation is achieved by the precise construction of the probe based on a core structure of the phospholipid, phosphatidylethanolamine (PtdEtn). If left unmodified, PtdEtn can be enzymatically cleaved by a variety of enzymes. However, if a bulky moiety is placed at the sn-2 position of the glycerol backbone without a spacer, only cleavage by PC-PLC is observed. 22 Our lab exploited this selective cleavage to design a next-generation activatable probe selective for PC-PLC. The final goal would be to design a probe that can more easily delineate cancerous tissue from healthy tissue.
Along with the selectivity achieved by the PtdEtn backbone, to build the activatable probe, a precise fluorophore/quencher pair must be implemented. The former has already been explored in our previous research with the fluorophore, pyropheophorbide a (Pyro, λ ex = 410 and 665 nm; λ em = 670−725 nm). Pyro achieves two goals: first, it is bulky enough to prevent cleavage of the phospholipid by any enzyme other than PC-PLC (as described above) and second, it fluoresces in the near-infrared (NIR) window. NIR fluorophores have been of interest recently because the NIR window is known for low autofluorescence, minimal absorption by water and hemoglobin, and low tissue scattering. Notable examples are indocyanine green or IRDye 800CW, both of which fluoresce in the NIR window and can be observed by detectors with tissue depth penetration of up to 1 cm.
2,33−36 The relative ease of detection of a NIR fluorophore like Pyro makes it an ideal candidate. An additional feature of Pyro is that it is a known photosensitizing agent, therefore our probe could be used not only for detection of cancer but also for treatment through the production of singlet oxygen when stimulated at the proper wavelength. 37−39 Despite the utility of Pyro as a NIR fluorophore, to create an activatable smart probe, the fluorescence must be quenched when not in the presence of the activating enzyme, PC-PLC. This is achieved by coupling a quenching moiety to the smart probe. Previously, our laboratory used the NIR Black Hole Quencher-3 (BHQ-3, absorbance range 620−730 nm) because it precisely absorbed the fluorescence emitted by Pyro through Forster resonance energy transfer. 22 The completed probe Pyro-PtdEtn-BHQ was successfully isolated by our lab (Scheme 1) and tested against various sources of PC-PLC.
In previously published papers, we reported the biological testing of Pyro-PtdEtn-BHQ against a series of phospholipases, including PC-PLC. Testing on cancer cells was carried out with DU145 human prostate cancer cell line, which has increased PC-PLC levels, and in vivo studies were performed on mouse models bearing DU145 tumors. 22−24 Despite the success of Pyro-PtdEtn-BHQ, BHQ-3 has been shown to experience stability problems in vivo due to the presence of an azo bond in the structure.
2,40−44 Moreover, the shelf-life of Pyro-PtdEtn-BHQ chloroform solution is less than 2 months, which makes it inconvenient for practical use as it requires freshly synthesized probes. The synthesis is complicated, and the overall yield of Pyro-PtdEtn-BHQ is as low as 15%. 22 Because of the quenching range afforded by BHQ-3, it has been used in a variety of fluorescent probes.
2, 44 Unfortunately, as was just mentioned, one of the drawbacks noted for BHQ-3 is the instability in the azo bond present in its structure.
2,40−44
A 2015 article published by Uddin et al. exploits the ease of cleavage of the azo bond of BHQ-3 as a probe activation mechanism to monitor hypoxia in mouse models. 44 Although this example uses the azo bond for advantageous purposes, the 
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2,40−44 An alternative quenching moiety with similar quenching capabilities but without an unstable azo bond could lead to a new generation of more stable activatable probes.
In this paper, we present the development of a new activatable smart probe that incorporates an alternative, more stable quenching moiety: QSY21, which has a similar quenching range (580−720 nm) to BHQ-3 (620−730 nm). Both quench in the NIR range, but their difference lies in their structures as QSY21 does not contain an azo bond (see structure in Scheme 2) and is therefore considered to be more stable. Moreover, a variety of activatable smart probes have already been synthesized using QSY21 to detect biological processes. 42,45−58 This paper presents the synthesis and initial biological evaluation of the novel PC-PLC selective probe, Pyro-PtdEtn-QSY.
■ RESULTS AND DISCUSSION
When the initial Pyro-PtdEtn-BHQ activatable probe was developed, it required the use of a BOC-protected phosphatidylethanolamine (LysoPtdEtn-BOC, see Scheme 1). By protecting the primary amine of the phospholipid we were able to prevent the coupling of the Pyro moiety at that position and saw exclusive substitution at the desired sn-2 position, which is required to achieve selective cleavage via PC-PLC. 22 Although the use of the LysoPtdEtn-BOC was feasible, it would have been more economical to use the unprotected phospholipid LysoPtdEtn. Unfortunately, when BHQ-3-SE was reacted with unprotected LysoPtdEtn, the desired product, LysoPtdEtn-BHQ, could not be isolated.
However, when unprotected conditions were tested using the azo-free quenching moiety, QSY21 (as succinimidyl ester, QSY21-SE), the desired product, LysoPtdEtn-QSY, was isolated in decent yield as a blue oil (Scheme 2). A detected side product was the product of hydrolysis of QSY21-SE; this did not inhibit the production or isolation of LysoPtdEtn-QSY. Not using a BOC protecting group proved to be not only financially advantageous but it also reduced the number of synthetic steps as we no longer had to remove the protecting group. An additional disadvantage of BOC-deprotecting step was partial chemical cleavage of ester bonds at the glycerol backbone under the strong acidic conditions that dramatically decreased the yield of Pyro-PtdEtn (20%, Scheme 1). 22 That is why this alteration most likely is responsible for the higher yield and cleaner product obtained.
Once LysoPtdEtn-QSY was isolated, Pyro is coupled to the sn-2 position of the phospholipid using a carbodiimide, N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (EDC·HCl). An excess of Pyro and EDC·HCl is used to drive the reaction toward the desired product, Pyro-PtdEtn-QSY (Scheme 2). Initially, Pyro appears green but once incorporated into the probe, its fluorescence is quenched by QSY21 and the fully assembled probe, Pyro-PtdEtn-QSY, appears aquamarine. This stark color change between Pyro and Pyro-PtdEtn-QSY simplifies the product isolation using column chromatography. The overall yield of Pyro-PtdEtn-QSY was as high as 61%, more than 4 times higher than for Pyro-PtdEtn-BHQ. 22 The shelf-life of Pyro-PtdEtn-QSY chloroform solution by now is more than 8 months, which makes it an ideal probe for practical use.
With Pyro-PtdEtn-QSY in hand, we set out to test its selective activation by PC-PLC. To confirm its specificity, the probe was exposed to PC-PLC as well as several other phospholipases, including sphingomyelinase (SMase), sPLA2 (IB porcine), and phospholipase D (PLD). In this (and next) experiment, the probe was incorporated into lipid nanoparticles (LNP) in 140 mM NaCl−10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer, pH 7.4, which we have previously found optimal for LNP stability and in vitro experiments. 59 It was excited at 409 nm, and emission was measured at 665 nm on a plate reader (SpectraMax M5, Molecular Devices). When Pyro-PtdEtn-QSY was exposed to PC-PLC, an increase of fluorescence was observed, whereas the other phospholipases did not yield any significant increase in fluorescence (Figure 1) .
Because of the success of the initial enzyme tests, further experiments were conducted to see if the fluorescence of PyroPtdEtn-QSY could be restored when exposed to PC-PLC under conditions more closely related to the intended translational use of the probe. Rather than excitation and emission experiments conducted at a single wavelength in a plate reader, we used an IVIS Spectrum imaging system with an excitation filter range of 415−445 nm (430 nm filter) and detected the emission in the 650−670 nm range (660 nm filter). For this, Pyro-PtdEtn-QSY was exposed to a buffered solution (140 mM NaCl−10 mM HEPES, pH 7.4, control) and several phospholipase isoforms, as described above. The Pyro-PtdEtn-QSY is exposed to PC-PLC. The fluorescence continues to increase with time, whereas the buffered control, PLD, and sPLA 2 (IB porcine) experiments remain quenched even after 6 h. This experiment confirms the conclusions of previous enzyme tests, demonstrating that Pyro-PtdEtn-QSY is successfully quenched until it is exposed to PC-PLC and fluorescence is restored. Moreover, this study is more accurate in confirming the potential translational use of the probe as a detector for PC-PLC in in vitro and in vivo models.
■ CONCLUSIONS
The NIR fluorescent probe Pyro-PtdEtn-QSY shows remarkable selectivity for PC-PLC. The synthesis of the probe does not require the use of protecting group chemistry essentially skipping a step that had been previously required for a PC-PLC selective probe. Additionally, probe stability is increased using a quenching moiety that does not have an azo bond. This structural change could lead to increased stability when exposed to biological conditions. Therefore, Pyro-PtdEtn-QSY is an excellent candidate for in vitro and in vivo studies of cancer cell types with increased PC-PLC levels, such as MDA-MB-231, triple negative breast cancer. 25 
■ EXPERIMENTAL PART
Materials and General Methods. Dry solvents were purchased from Acros Organics. Regular solvents were purchased from Fisher Scientific. Pyropheophorbide a (Pyro) was purchased from Frontier Scientific, Newark, DE. 1-Palmitoyl-2-hydroxy-sn-glycero-phosphoethanolamine (16:0 Lyso-phosphatidylethanolamine, LysoPtdEtn) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] ammonium salt (DSPE-PEG2000) in chloroform, 5 mg/mL, were purchased from Avanti Polar Lipids, Inc., Alabaster, AL. QSY21 succinimidyl ester (QSY-SE) was purchased from Thermo Fisher Scientific, Grand Island, NY. Other reagents/reactants were purchased from Sigma-Aldrich and used without further purification. Silica diol (Premium RF, 70A, 40−75 μm, product # -62570-01) and silica diol thin-layer chromatography plates (w/ UV254, glass backed, 200 μm, 10 × 20 cm 25/pk, product # -2914136) were purchased from Sorbtech Chromatography, Norcross, GA. All chemical reactions with QSY21 and/or Pyro were carried out in the dark under dry Ar. Matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra were recorded on a Bruker Ultraflex III MALDI TOF/TOF (Bruker Daltonics, Billerica, MA) using positivemode ionization with a terthiophene (Ter; 2,2′:5′,2″-terthiophene) matrix. Absorbance and fluorescence data, as well as time-dependent release of fluorescence, were measured using a SpectraMax M5 fluorescent plate reader (Molecular Devices, San Jose, CA) and an IVIS Spectrum in vivo imaging system (PerkinElmer, Hopkinton, MA).
Phospholipases. Phospholipases were obtained from Sigma-Aldrich (St. Louis, MO), dissolved in 140 mM NaCl− 10 mM HEPES buffer, pH = 7.4, and stored in aliquots at −80°C
. Mammalian phospholipase isoforms were used whenever available: sPLA2 (type IB, porcine pancreas), otherwise bacterial isoforms were employed: PC-PLC (Bacillus cereus), SMase (Benthesicymus cereus), and PC-PLD (Streptomyces chromofuscus).
Experimental Procedures. Synthesis of LysoPtdEtn-QSY. LysoPtdEtn (0.050 g, 0.110 mmol) and QSY-SE (0.020 g, 0.0245 mmol) were added to a 100 mL round-bottom flask with stir bar, followed by dry acetonitrile (∼50 mL), diisopropylethylamine (40 μL, 0.230 mmol), and 4-(dimethylamino)pyridine (DMAP, 0.0087 g, 0.0712 mmol). The reaction flask was purged with argon and covered in aluminum foil. The blue reaction solution was stirred for 2 days. Reaction progress was tested via thin-layer chromatography (TLC) on functionalized silica diol (Sorbtech cat # 2933187) using a methanol/chloroform solution (5:95). The product was observed at R f = 0.47. The reaction solution was concentrated in vacuo until ∼3 mL remained. The reaction solution was loaded onto a silica diol (Sorbtech cat # 62570-01) column. A gradient of methanol/chloroform eluent was used (0:100 to 20:80) to elute several blue fractions. The blue fractions were tested via TLC, and on the basis of these results, the proper fractions were concentrated to a dark blue oil. The oil was left under vacuum overnight to reveal the product (0.0239 g, 0.0214 mmol, 87% yield). The product, LysoPtdEtn-QSY, was confirmed by MALDI mass spectrometry and UV−vis spectrometry ( Supporting Information, SI) .
Synthesis of Pyro-PtdEtn-QSY. LysoPtdEtn-QSY (0.0190 g, 0.0170 mmol) was put into a 20 dram vial charged with a stir bar, followed by Pyro (0.0118 g, 0.0542 mmol), N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (EDC·HCl, 0.1848 g, 0.9640 mmol), DMAP (0.0225 g, 0.1841 mmol), and dry dichloromethane (∼4 mL). The reaction vial was purged with argon, covered in foil, and allowed to stir for 72 h. The reaction was monitored by TLC on silica diol plates (5:95, methanol/chloroform) until an aquamarine spot appeared at R f = 0.6. The reaction solution was loaded onto a silica diol (Sorbtech cat # 62570-01) column (∼0.5 cm). Methanol/chloroform (1:99) was used to elute an aquamarine band. The aquamarine band was concentrated to an oil and placed under vacuum overnight to yield an aquamarine oil. The oil was then picked up in minimal chloroform and placed on a silica diol preparative TLC plate. The plate was eluted with 10:90 methanol/ chloroform. An aquamarine band was collected between R f 's 0.70 and 0.75. The silica was collected and stirred with 10:90 methanol/chloroform. After filtering off the sorbent, the solution was concentrated and underwent second preparative TLC to get rid of fluorescent impurities (Pyro acid). The product was isolated as an oil that was lyophilized overnight (0.0194 g, 0.0119 mmol, 70% yield). The overall yield after two-step synthesis is 61%. The product was confirmed by MALDI mass spectrometry and UV−vis spectrometry (SI).
Preparation of Pyro-PtdEtn-QSY-Loaded Lipid Nanoparticles. DSPE-PEG2000 (1 mL of 5 mg/mL solution in CHCl 3 , 1.78 μmol, 97% mol) and Pyro-PtdEtn-QSY in CHCl 3 (55 nmol, 3% mol) were mixed in a 15 mL glass flask. (PyroPtdEtn-QSY concentration in the initial chloroform solution was determined using the Beer−Lambert law by measuring the optical density at 410 nm and employing an extinction coefficient of 110 000 M/cm.) The solvent was evaporated under nitrogen flow. The obtained lipid film was dried under high vacuum overnight. The flask was then flushed with Ar and held in the water bath at 80°C for 3 min, then rehydrated with 1 mL of hot (80°C) degassed buffer solution under Ar flow. Buffer (140 mM NaCl−10 mM HEPES) was used at pH 7.4. The mixture was vortexed until an optically clear dispersion was obtained and allowed to cool down. Upon reaching room temperature, the solution was filtered through a 0.22 μm MILLEX-GV filter.
Enzyme-Mediated Probe Cleavage. Fluorescence experiments: 90 μL of phospholipase solution in buffer (140 mM NaCl−10 mM HEPES, pH = 7.4) was placed into a black wall flat clear bottom 96-well plate (10 units per well). PyroPtdEtn-QSY lipid dispersion (10 μL) in buffer (140 mM NaCl−10 mM HEPES, pH = 7.4) was added to the phospholipase to a final concentration of 1 mM. Fluorescence was monitored over time at 37°C on a Molecular Devices SpectraMax M5 plate reader under excitation 409 nm and emission 665 nm.
Enzyme-Mediated Probe Cleavage: IVIS Spectrum Experiments. The IVIS Spectrum (PerkinElmer, Hopkinton, MA) is an advanced preclinical optical imaging system ideal for fluorescence imaging in vivo and in vitro. Black wall clear bottom 96-well plates were prepared as above with solutions of 1 mM Pyro-PtdEtn-QSY and 10 units of phospholipases in 140 mM NaCl−10 mM HEPES buffer, pH = 7.4. Fluorescence was monitored over time at 37°C with excitation between 415 and 445 nm (430 nm filter) and emission at 650−670 nm (660 nm filter).
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b00635. 
